Table 1.

Main demographic and clinical characteristics of RRMS patients treated with cladribine in our center

Variable	Cladribine-treated RRMS patients in our center (n = 56)
Male/female (%)	17 (30%)/39 (70%)
Mean age (SD) [years]	33.8 (8.1)
Median disease duration (IQR) [years]	5.2 (2.1–11.1)
Median EDSS (IQR)	1.5 (1.0–2.0)
Median treatment duration* (IQR) [months]	15.8 (12.9–20.5)

*at the last available follow-up (August 25th 2020)

EDSS Expanded Disability Status Scale; IQR interquartile range; RRMS relapsing–remitting multiple sclerosis; SD standard deviation